Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Improving our understanding of ependymomas in the spinal cord
Comprehensive molecular characterization of paediatric spinal ependymomas
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment
Improving our understanding of leukaemia that has spread throughout the body
Defining the tumour microenvironment in extramedullary acute leukaemia
Discovering the differences between craniopharyngiomas that regrow after treatment and those that don't
Molecular profiling of relapsing craniopharyngioma
How do childhood brain tumours start?
Defining the cellular origins of neonatal and paediatric brain tumours
Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies